Table 1.

Evidence Relating IGFBP-2 to Advanced Cancer

	In vitro	In vivo
Adrenal Cancer	no reports	Increased in the serum of patients [165]
		Increased expression in malignant vs. benign human tumors [166]
Bladder Cancer	Increased invasion of bladder cancer cells [167]	Increased expression in invasive disease [168]
Breast Cancer	Denotes anti-estrogen resistant BCa cell lines [169]	Increased expression in invasive disease [156]
CNS cancers	Increased migration of SHEP cells [14]	Correlated with decreased survival [171]
	Increases glioma cell invasion [170]	Increased with tumor grade [172]
	Assoc. with expression of Invasion genes [159]	Increased with progression [173]
Gastric Cancer	Expressed in multiple cancer cell lines [174]	Increased in peritoneal metastasis [176]
	Associated with increased proliferation [175]	Associated with advanced disease [137]
Ovarian Cancer	Increased invasion [175]	Increased in serum of ovarian cancer patients [177]
		Increased in ovarian tissue during progression [178]
		Increased in, and associated with increased risk of advanced disease [175] [179]
Prostate Cancer	Increased in metastatic, AI PCa cell lines [51]	Serum levels have inverse correlation to advanced disease [180]
	Loss of proteolytic degradation in AI PCa [145]	Increased expression in AI PCa [75]
	Decreased time to attain AI [80]